Therapeutics Md, Inc. - Understand $txmd stock

$TXMD Market Cap: $14.53 Million

Research Board Inbox Deep Research Not Interested Shortlisted

Financial Snapshot

Revenue

$1.596M

TTM

Gross Margin

100.0%

TTM

Net Earnings

-$3.316M

TTM

Current Assets

$12.15M

Q3 2024

Current Liabilities

$5.976M

Q3 2024

Current Ratio

203.38%

Q3 2024

Total Assets

$39.55M

Q3 2024

Total Liabilities

$12.46M

Q3 2024

Book Value

$27.09M

Q3 2024

Cash

$5.047M

Q3 2024

P/E

-4.382

Nov 29, 2024 EST

Free Cash Flow

-$8.026M

TTM

Revenues

Revenue YoY Change

Revenues

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006
Revenue	$1.302M	$69.96M	$86.95M	$64.87M	$49.65M	$16.10M	$16.78M	$19.36M	$20.14M	$15.03M	$8.780M	$3.820M	$2.090M	$1.240M	$0.00	$0.00	$0.00	$0.00
YoY Change	-98.14%	-19.54%	34.03%	30.67%	208.37%	-4.05%	-13.33%	-3.87%	34.0%	71.18%	129.84%	82.78%	68.55%

Expenses

Cost Of Revenues

Gross Profit

Gross Profit Margin

Gross Profit

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006
Revenue	$1.302M	$69.96M	$86.95M	$64.87M	$49.65M	$16.10M	$16.78M	$19.36M	$20.14M	$15.03M	$8.780M	$3.820M	$2.090M	$1.240M	$0.00	$0.00	$0.00	$0.00
Cost Of Revenue		$1.397M	$18.84M	$15.97M	$6.330M	$2.740M	$2.640M	$4.190M	$4.510M	$3.670M	$1.960M	$1.350M	$950.0K	$560.0K
Gross Profit	$1.302M	$68.57M	$68.11M	$48.90M	$43.31M	$13.36M	$14.14M	$15.17M	$15.64M	$11.35M	$6.820M	$2.470M	$1.140M	$690.0K
Gross Profit Margin	100.0%	98.0%	78.33%	75.38%	87.24%	82.98%	84.27%	78.36%	77.66%	75.52%	77.68%	64.66%	54.55%	55.65%

Selling, General & Admin Expense

Research & Development

Depreciation, Depletion & Amortization

SGA Expense to Gross Profit Ratio

R&D To Gross Profit Ratio

DDA To Gross Profit Ratio

Operating Expenses Total

Operating Profits/Loss

Operational Expenses

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006
Selling, General & Admin	$8.903M	$57.90M	$200.8M	$193.0M	$174.1M	$116.0M	$57.70M	$51.35M	$28.72M	$22.12M	$19.01M	$14.07M	$6.410M	$3.460M	$630.0K	$400.0K	$90.00K	$140.0K
YoY Change	-84.62%	-71.16%	4.06%	10.83%	50.11%	101.02%	12.37%	78.8%	29.84%	16.36%	35.11%	119.5%	85.26%	449.21%	57.5%	344.44%	-35.71%
% of Gross Profit	683.79%	84.45%	294.8%	394.6%	402.01%	868.19%	408.06%	338.5%	183.63%	194.89%	278.74%	569.64%	562.28%	501.45%
Research & Development		$0.00	$7.086M	$10.43M	$19.79M	$27.30M	$33.85M	$53.94M	$72.04M	$43.22M	$13.55M	$4.490M	$110.0K	$70.00K
YoY Change		-100.0%	-32.06%	-47.3%	-27.51%	-19.35%	-37.25%	-25.12%	66.68%	218.97%	201.78%	3981.82%	57.14%
% of Gross Profit		0.0%	10.4%	21.33%	45.69%	204.34%	239.39%	355.57%	460.61%	380.79%	198.68%	181.78%	9.65%	10.14%
Depreciation & Amortization	$100.0K	$600.0K	$800.0K	$800.0K	$400.0K	$290.0K	$210.0K	$130.0K	$60.00K	$50.00K	$60.00K	$60.00K	$60.00K	$20.00K	$0.00
YoY Change	-83.33%	-25.0%	0.0%	100.0%	37.93%	38.1%	61.54%	116.67%	20.0%	-16.67%	0.0%	0.0%	200.0%
% of Gross Profit	7.68%	0.88%	1.17%	1.64%	0.92%	2.17%	1.49%	0.86%	0.38%	0.44%	0.88%	2.43%	5.26%	2.9%
Operating Expenses	$9.825M	$67.38M	$207.9M	$204.4M	$194.5M	$143.6M	$91.77M	$105.4M	$100.8M	$65.40M	$32.62M	$18.61M	$6.570M	$3.550M	$630.0K	$400.0K	$90.00K	$140.0K
YoY Change	-85.42%	-67.59%	1.68%	5.1%	35.48%	56.46%	-12.95%	4.56%	54.16%	100.49%	75.28%	183.26%	85.07%	463.49%	57.5%	344.44%	-35.71%
Operating Profit	-$8.523M	$1.191M	-$139.8M	-$155.5M	-$151.2M	-$130.2M	-$77.63M	-$90.25M	-$85.18M	-$54.05M	-$25.80M	-$16.14M	-$5.430M	-$2.860M
YoY Change	-815.62%	-100.85%	-10.14%	2.86%	16.12%	67.74%	-13.98%	5.95%	57.59%	109.5%	59.85%	197.24%	89.86%

Interest Expenses

Interest Expenses To Operating Income %

Other Expense/Income

Interest & Other Expense/Income

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006
Interest Expense	$300.0K	$36.07M	$32.92M	$28.58M	$17.38M	-$4.680M		$10.00K	$20.00K	-$220.0K	-$2.640M	-$1.910M	-$60.00K	$0.00	$0.00
YoY Change	-99.17%	9.56%	15.17%	64.43%	-471.41%			-50.0%	-109.09%	-91.67%	38.22%	3083.33%
% of Operating Profit		3028.13%
Other Income/Expense, Net	$781.0K	-$117.0K	-$32.65M	$600.0K	$2.500M	$2.280M	$700.0K	$370.0K	$100.0K	$50.00K	$30.00K	-$6.760M	-$30.00K	$0.00	$0.00	$0.00	$40.00K	$50.00K
YoY Change	-767.52%	-99.64%	-5540.83%	-76.0%	9.65%	225.71%	89.19%	270.0%	100.0%	66.67%	-100.44%	22433.33%				-100.0%	-20.0%

Income/Loss

Pretax Income

Income Tax

Net Profits/Loss

Pretax Income YoY Change

Income Tax Rate

Net Profits/Loss YoY Change

Basic EPS

Net Income To Revenue Ratio

Pretax & Net Income

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006
Pretax Income	-$7.742M	$1.074M	-$172.4M	-$183.5M	-$176.1M	-$132.6M	-$76.93M	-$89.88M	-$85.08M	-$54.22M	-$28.42M	-$35.12M	-$12.91M	-$2.870M	-$630.0K	-$400.0K	-$50.00K	-$90.00K
YoY Change	-820.86%	-100.62%	-6.05%	4.19%	32.82%	72.39%	-14.41%	5.64%	56.92%	90.78%	-19.08%	172.04%	349.83%	355.56%	57.5%	700.0%	-44.44%
Income Tax	-$43.00K	$0.00	$0.00					$0.00		$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
% Of Pretax Income		0.0%
Net Earnings	-$10.28M	$112.0M	-$172.4M	-$183.5M	-$176.1M	-$132.6M	-$76.93M	-$89.88M	-$85.08M	-$54.22M	-$28.42M	-$35.12M	-$12.91M	-$2.870M	-$1.650M	-$400.0K	$170.0K	$370.0K
YoY Change	-109.18%	-164.96%	-6.05%	4.19%	32.82%	72.39%	-14.41%	5.64%	56.92%	90.78%	-19.08%	172.04%	349.83%	73.94%	312.5%	-335.29%	-54.05%
Net Earnings / Revenue	-789.4%	160.08%	-198.29%	-282.9%	-354.79%	-823.73%	-458.46%	-464.26%	-422.44%	-360.75%	-323.69%	-919.37%	-617.7%	-231.45%
Basic Earnings Per Share	-$0.98	$12.41	-$21.66
Diluted Earnings Per Share	-$0.98	$11.96	-$21.66M	-$665.8K	-$715.0K	-$589.3K	-$374.3K	-$458.4K	-$491.3K	-$362.1K	-$222.8K	-$383.3K	-$206.5K	-$74.95K	-$23.57M	-$13.33M	$8.500M	$18.50M

Assets & Liabilities

Cash & Short-Term Investments

Cash & Equivalents

Cash To Operating Expenses Ratio

Inventory

Receivables

Total Short-Term Assets

Property, Plant And Equipment

Long-Term Investments

Total Long-Term Assets

Total Assets

Net Income To Total Assets Percentage

Accounts Payable

Short-Term Debt

Long Term Debt Due

Total Short-Term Liabilities

Long-Term Debt

Other Long-Term Liabilities

Total Long-Term Liabilities

Total Liabilities

Short-Term To Long-Term Debt Ratio

Short-Term Assets To Debt Ratio

Long-Term Debt To Net Income Ratio

Assets & Liabilities

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006
Cash & Short-Term Investments	$4.327M	$38.07M	$65.12M	$80.50M	$160.8M	$161.6M	$127.1M	$131.5M	$64.70M	$51.40M	$54.20M	$1.600M	$100.0K	$400.0K	$0.00	$100.0K	$400.0K
YoY Change	-88.63%	-41.55%	-19.1%	-49.94%	-0.5%	27.14%	-3.35%	103.25%	25.88%	-5.17%	3287.5%	1500.0%	-75.0%		-100.0%	-75.0%
Cash & Equivalents																$100.0K	$400.0K
Short-Term Investments
Other Short-Term Assets	$4.379M	$17.28M	$10.55M	$7.500M	$11.40M	$10.80M	$6.600M	$1.300M	$2.200M	$1.300M	$2.300M	$800.0K	$500.0K	$0.00	$100.0K			$1.000M
YoY Change	-74.66%	63.86%	40.64%	-34.21%	5.56%	63.64%	407.69%	-40.91%	69.23%	-43.48%	187.5%	60.0%		-100.0%
Inventory			$7.622M	$8.000M	$11.90M	$3.300M	$1.500M	$1.100M	$700.0K	$1.200M	$1.000M	$1.600M	$600.0K	$600.0K
Prepaid Expenses
Receivables			$36.18M	$32.40M	$24.40M	$11.10M	$4.300M	$4.500M	$3.000M	$2.200M	$1.700M	$700.0K	$0.00	$0.00	$0.00	$0.00	$100.0K	$100.0K
Other Receivables			$0.00	$0.00	$0.00	$0.00	$0.00	$1.000M	$0.00	$200.0K	$200.0K	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Total Short-Term Assets	$11.80M	$55.35M	$119.5M	$128.4M	$208.4M	$186.8M	$139.6M	$139.4M	$70.70M	$56.20M	$59.40M	$4.600M	$1.200M	$1.100M	$100.0K	$100.0K	$500.0K	$1.100M
YoY Change	-78.69%	-53.67%	-6.96%	-38.39%	11.56%	33.81%	0.14%	97.17%	25.8%	-5.39%	1191.3%	283.33%	9.09%	1000.0%	0.0%	-80.0%	-54.55%
Property, Plant & Equipment	$6.873M	$7.658M	$9.433M	$11.50M	$12.60M	$500.0K	$400.0K	$500.0K	$200.0K	$100.0K	$100.0K	$100.0K	$0.00	$100.0K	$0.00			$800.0K
YoY Change	-10.25%	-18.82%	-17.97%	-8.73%	2420.0%	25.0%	-20.0%	150.0%	100.0%	0.0%	0.0%		-100.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$58.00K	$253.0K	$253.0K	$300.0K	$500.0K	$600.0K	$100.0K	$100.0K	$1.200M	$1.600M	$1.900M	$1.000M	$100.0K	$0.00	$800.0K
YoY Change	-77.08%	0.0%	-15.67%	-40.0%	-16.67%	500.0%	0.0%	-91.67%	-25.0%	-15.79%	90.0%	900.0%		-100.0%
Total Long-Term Assets	$31.51M	$35.11M	$50.00M	$53.20M	$57.60M	$25.20M	$3.600M	$3.100M	$3.000M	$2.900M	$2.600M	$1.300M	$200.0K	$100.0K	$700.0K	$0.00	$0.00	$800.0K
YoY Change	-10.24%	-29.79%	-6.01%	-7.64%	128.57%	600.0%	16.13%	3.33%	3.45%	11.54%	100.0%	550.0%	100.0%	-85.71%			-100.0%
Total Assets	$43.31M	$90.46M	$169.5M	$181.6M	$266.0M	$212.0M	$143.2M	$142.5M	$73.70M	$59.10M	$62.00M	$5.900M	$1.400M	$1.200M	$800.0K	$100.0K	$500.0K	$1.900M
YoY Change
Accounts Payable	$27.00K	$2.162M	$20.32M	$21.10M	$19.20M	$22.70M	$4.100M	$7.400M	$3.100M	$6.300M	$2.100M	$1.600M	$300.0K	$100.0K	$100.0K	$0.00	$0.00	$100.0K
YoY Change	-98.75%	-89.36%	-3.71%	9.9%	-15.42%	453.66%	-44.59%	138.71%	-50.79%	200.0%	31.25%	433.33%	200.0%	0.0%			-100.0%
Accrued Expenses	$2.724M	$17.24M	$40.69M	$28.80M	$21.20M	$12.20M	$7.600M	$6.800M	$7.300M	$3.600M	$3.100M	$600.0K	$400.0K	$100.0K		$0.00	$100.0K	$0.00
YoY Change	-84.2%	-57.63%	41.28%	35.85%	73.77%	60.53%	11.76%	-6.85%	102.78%	16.13%	416.67%	50.0%	300.0%			-100.0%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$2.400M	$0.00	$200.0K	$0.00	$0.00	$0.00
YoY Change												-100.0%		-100.0%
Long-Term Debt Due		$0.00	$188.3M
YoY Change		-100.0%
Total Short-Term Liabilities	$6.854M	$46.84M	$252.9M	$59.20M	$53.00M	$41.10M	$13.30M	$15.00M	$10.70M	$10.70M	$7.300M	$3.600M	$3.200M	$200.0K	$1.200M	$0.00	$100.0K	$100.0K
YoY Change	-85.37%	-81.48%	327.18%	11.7%	28.95%	209.02%	-11.33%	40.19%	0.0%	46.58%	102.78%	12.5%	1500.0%	-83.33%		-100.0%	0.0%
Long-Term Debt	$0.00	$0.00	$0.00	$237.7M	$194.6M	$73.40M	$0.00	$0.00	$0.00	$0.00	$0.00	$3.600M	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change			-100.0%	22.15%	165.12%						-100.0%
Other Long-Term Liabilities	$7.168M	$8.476M	$10.20M	$8.700M	$9.100M						$0.00	$200.0K	$0.00					$100.0K
YoY Change	-15.43%	-16.92%	17.26%	-4.4%							-100.0%
Total Long-Term Liabilities	$7.168M	$8.476M	$10.20M	$246.4M	$203.7M	$73.40M	$0.00	$0.00	$0.00	$0.00	$0.00	$3.800M	$0.00	$0.00	$0.00	$0.00	$0.00	$100.0K
YoY Change	-15.43%	-16.92%	-95.86%	20.96%	177.52%						-100.0%						-100.0%
Total Liabilities	$14.02M	$55.32M	$263.1M	$305.6M	$256.8M	$114.5M	$13.30M	$15.00M	$10.70M	$10.70M	$7.300M	$7.400M	$3.200M	$200.0K	$1.200M	$0.00	$100.0K	$200.0K
YoY Change	-74.65%	-78.98%	-13.91%	19.0%	124.28%	760.9%	-11.33%	40.19%	0.0%	46.58%	-1.35%	131.25%	1500.0%	-83.33%		-100.0%	-50.0%

Ownership

Basic Shares Outstanding

Diluted Shares Outstanding

Preferred Stock

Treasury Stock Shares

Stock Issuance & Repurchase

Ownership Data

Concept	2023	2022	2021	2020	2019
Basic Shares Outstanding	10.44M shares	9.028M	398.0M	275.6M	246.4M
Diluted Shares Outstanding	10.44M shares	9.366M	7.960M
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Book Value

Free Cash Flow

Free Cash Flow YoY

Free Cash Flow Margin

Dividends

Stock Price

Market Cap: $14.531 Million

About TherapeuticsMD, Inc.

TherapeuticsMD, Inc. operates as a pharmaceutical company. The company is headquartered in Boca Raton, Florida and currently employs 1 full-time employees. The company went IPO on 2001-01-31. The company receives royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. The company granted a license to commercialize IMVEXXY, BIJUVA, and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands and assigned its exclusive license to commercialize ANNOVERA to Mayne Pharma. IMVEXXY (estradiol vaginal inserts) pharmaceutical product is for the treatment of moderate-to-severe dyspareunia. BIJUVA pharmaceutical product is a Food and Drug Administration (FDA)-approved bioidentical hormone therapy combination of estradiol and progesterone in a single, oral capsule for the treatment of moderate-to-severe vasomotor symptoms due to menopause in women with a uterus. ANNOVERA pharmaceutical product is a one-year ring-shaped contraceptive vaginal system (CVS).

Industry: Pharmaceutical Preparations Peers: Anebulo Pharmaceuticals, Inc. Aquestive Therapeutics, Inc. Dare Bioscience, Inc. Clearside Biomedical, Inc. EYENOVIA, INC. JOHNSON & JOHNSON Longboard Pharmaceuticals, Inc. SCYNEXIS INC